Auckland-based skin cancer doctor and entrepreneur Professor Sharad Paul is pushing Healthy Skin Lab toward a larger United States expansion after its tinted SPF 50 moisturiser found a market through Amazon without a heavy launch campaign. Idealog reported on 2 July that the New Zealand skincare start-up is seeking $4 million in primary growth capital after early US demand gave the company confidence to build manufacturing, inventory and distribution capacity.
The founder story matters because this is not a celebrity beauty brand chasing a quick trend. Paul is a long-standing Auckland clinician, author and skin cancer specialist whose Skin Surgery Clinic operates in Blockhouse Bay. Healthy Skin Lab says it was founded around his view that skin products should be backed by evidence and overall health thinking, not just cosmetic positioning. That medical origin gives the company a different lane in a crowded skincare market.
The product at the centre of the current expansion is Protect, a tinted SPF 50 moisturiser. Idealog reported that it is believed to be the first New Zealand skincare sunscreen registered with the United States Food and Drug Administration as an over-the-counter drug product. That is commercially important because sunscreen in the US is regulated differently from ordinary cosmetics. A product that clears the relevant pathway can be sold into channels that treat sun protection as a health category, including pharmacies and wellness retailers.
Healthy Skin Lab's early traction appears to have been demand-led. The company first introduced Protect into the US through Amazon as a test market, without a formal advertising campaign, paid influencer programme or major marketing push. Idealog reported cumulative sales of more than $2 million over two years, more than 2,000 Amazon subscribers and repeated sell-outs after independent beauty review attention.
The next challenge is less glamorous than the product story. Paul told Idealog the limitation is now manufacturing enough, holding enough inventory and building the team needed to support larger channels. The company wants capital to appoint a chief executive and operating team, expand manufacturing capacity, increase stock, support Amazon and direct-to-consumer growth, and pursue wholesale or physical retail distribution.
For Auckland's business scene, this is a useful founder example because it shows how a local specialist service can become an export product business. Paul did not start from a generic consumer brand template. He started from clinical expertise, product formulation, regulatory requirements and a clear problem: sun protection that customers would actually use. The export opportunity is emerging because that specialist credibility has met a large market with high skincare spending.
The risk is also clear. A product that sells well on Amazon is not automatically ready for pharmacy chains, international logistics, inventory financing and retail distribution. Consumer health products need consistency, claims discipline, regulatory confidence and reliable supply. A strategic investor may help if they bring market access and operating experience, not just cash. Healthy Skin Lab now has to move from organic validation to operational scale. If it succeeds, an Auckland medical founder will have turned specialist skin knowledge into a more serious export play.
